{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:47:16Z","timestamp":1789786036893,"version":"4.0.1"},"reference-count":0,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.4155\/fmc.09.32","type":"journal-article","created":{"date-parts":[[2009,6,10]],"date-time":"2009-06-10T16:15:36Z","timestamp":1244650536000},"page":"243-248","source":"Crossref","is-referenced-by-count":2,"title":["Interview with Dr Bernard P\u00e9Coul, Executive Director of the Drugs for Neglected Diseases Initiative"],"prefix":"10.1080","volume":"1","author":[{"given":"Bernard","family":"P\u00e9coul","sequence":"first","affiliation":[{"name":"Drugs for Neglected Diseases Initiative, 15 Chemin Louis-Dunant, Geneva, 1202, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2009,6,10]]},"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc.09.32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:48:35Z","timestamp":1716493715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc.09.32"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["10.4155\/fmc.09.32"],"URL":"https:\/\/doi.org\/10.4155\/fmc.09.32","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"value":"1756-8919","type":"print"},{"value":"1756-8927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}